Sentence examples for demonstrate no efficacy from inspiring English sources

Several candidate microbicides from the nonspecific and moderately specific classes have been evaluated in clinical trials and either demonstrate no efficacy or promote HIV acquisition in women [20], [21], [52], [53].

MR16-1 demonotratefficacyfinacy in Tsk-1 mice.

14 In 2010, the drug was removed from the market after confirmatory studies contradicted the initial studies, demonstrating no efficacy and increased mortality.

Unfortunately, the study demonstrates no efficacy of artificial liver support systems in decreasing cytokine levels, and the authors conclude that a high rate of cytokine production that exceeds the rate of detoxification probably accounts for their findings.

Administration of the gD2-AS04 candidate vaccine demonstrated no overall efficacy against genital herpes disease.

FTS was administered at doses and schedules reported to give optimal antitumor efficacy in some pancreatic tumor models, but it demonstrated no significant antitumor efficacy in the Panc-1 xenograft model: the %T/C for that group, calculated on day 20, was 52%, representing a 48% reduction in tumor growth (P=0.337).

A control conjugate without PEG demonstrated no improvement in efficacy over untargeted CPT emphasizing the importance of spacer between the anticancer compounds and targeting moiety.

The study by Collantes et al.[ 18] demonstrated no difference in efficacy between etoricoxib and naproxen in treating patients with rheumatoid arthritis, while the study by Matsumoto et al. demonstrated etoricoxib to be significantly more effective [ 17].

One study of a diclofenac topical liquid included an oral diclofenac comparator, and demonstrated no difference in efficacy between the two therapies in treatment for the pain of osteoarthritis in the knee [ 12].

Therefore, data from the current study are consistent with other reports demonstrating no differences in efficacy measures between AIs used as first-line treatment in patients with hormone-receptor-positive breast cancer.

McCann et al 28 concluded "that pazopanib demonstrates no reduction in efficacy compared to other approved angiogenesis inhibitors", which is in line with our findings that say 'there is no significant difference in first-line PFS outcomes between BEV+IFN and the TKIs SUN and PAZ'.